Neostem gets patent boost for heart drug

Neostem (NBS) has received a notice of allowance for what is the sixth granted or allowed U.S. patent for the company's AMR-001 drug, which is designed to preserve heart function after a severe heart attack.

In addition, the EU intends to grant two patents for AMR-001; these would be Neostem's first patents in the region.

AMR-001's total worldwide IP coverage is now 16 granted and allowed patents. (PR)

Comments (1)
  • User 9153621
    , contributor
    Comments (4) | Send Message
    NBS stock should begin to climb now as it nears the end of Phase II trials in 1st quarter.


    There appears to be growing public awareness and interest in a medley of RNA studies.


    General speculation and stock rise will quickly follow.


    Post 1st quarter, stock should dip then a flurry of articles will appear re-addressing NBS financial fundamentals.


    NBS "contract" services for other bio-engineering, pharmaceutical, and research companies will be noted. The nature of theses contracts will need to be thoroughly scrutinized. The revenue generated provides the operational funds that keep NBS viable. Without numerous, longitudinal, and tightly structured contracts, NBS reserve funds and the burn-through rate will play a pivot-able role.
    6 Jan 2014, 04:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs